Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma

Jian Min Wu, N. Skill, Mary Maluccio

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objectives: Lipids are linked to many pathological processes including hepatic steatosis and liver malignancy. This study aimed to explore lipid metabolism in hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). Methods: Serum lipids were measured in normal, HCV and HCV-HCC patients. Whole-genome microarray was performed to identify potential signature genes involved in lipid metabolism characterizing normal vs. HCV vs. HCV-HCC conditions. Results: Serum cholesterol was significantly reduced in HCV and HCV-HCC patients compared with normal controls, whereas there was no difference in glucose and triglycerides. Microarray analysis identified 224 probe sets with known functional roles in lipid metabolism (anova, 1.5-fold, P ≤ 0.001). Gene-mediated fatty acid (FA) de novo synthesis and uptake were upregulated in HCV and this upregulation was further enhanced in HCC. Genes involved in FA oxidation were downregulated in both the HCV and HCC groups. The abnormality of cholesterol metabolism in HCV was associated with downregulation of genes involved in cholesterol biosynthesis, absorption and transportation and bile acid synthesis; this abnormality was further intensified in HCC. Conclusions: Our data support the notion that HCV-related lipid metabolic abnormalities may contribute to hepatic steatosis and the development of cancer. Identification of these aberrations would stratify patients and improve treatment algorithms.

Original languageEnglish
Pages (from-to)625-636
Number of pages12
JournalHPB
Volume12
Issue number9
DOIs
StatePublished - Nov 2010

Fingerprint

Hepatitis C
Lipid Metabolism
Hepacivirus
Hepatocellular Carcinoma
Cholesterol
Lipids
Genes
Fatty Acids
Down-Regulation
Liver
Pathologic Processes
Fatty Liver
Microarray Analysis
Bile Acids and Salts
Serum
Neoplasms
Triglycerides
Up-Regulation
Genome
Glucose

Keywords

  • Hepatic steatosis
  • Hepatitis C virus (HCV)
  • Hepatocellular carcinoma (HCC)
  • Lipid metabolism

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. / Wu, Jian Min; Skill, N.; Maluccio, Mary.

In: HPB, Vol. 12, No. 9, 11.2010, p. 625-636.

Research output: Contribution to journalArticle

Wu, Jian Min ; Skill, N. ; Maluccio, Mary. / Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. In: HPB. 2010 ; Vol. 12, No. 9. pp. 625-636.
@article{f33623380b054218a4e4d87b3334035f,
title = "Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma",
abstract = "Objectives: Lipids are linked to many pathological processes including hepatic steatosis and liver malignancy. This study aimed to explore lipid metabolism in hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). Methods: Serum lipids were measured in normal, HCV and HCV-HCC patients. Whole-genome microarray was performed to identify potential signature genes involved in lipid metabolism characterizing normal vs. HCV vs. HCV-HCC conditions. Results: Serum cholesterol was significantly reduced in HCV and HCV-HCC patients compared with normal controls, whereas there was no difference in glucose and triglycerides. Microarray analysis identified 224 probe sets with known functional roles in lipid metabolism (anova, 1.5-fold, P ≤ 0.001). Gene-mediated fatty acid (FA) de novo synthesis and uptake were upregulated in HCV and this upregulation was further enhanced in HCC. Genes involved in FA oxidation were downregulated in both the HCV and HCC groups. The abnormality of cholesterol metabolism in HCV was associated with downregulation of genes involved in cholesterol biosynthesis, absorption and transportation and bile acid synthesis; this abnormality was further intensified in HCC. Conclusions: Our data support the notion that HCV-related lipid metabolic abnormalities may contribute to hepatic steatosis and the development of cancer. Identification of these aberrations would stratify patients and improve treatment algorithms.",
keywords = "Hepatic steatosis, Hepatitis C virus (HCV), Hepatocellular carcinoma (HCC), Lipid metabolism",
author = "Wu, {Jian Min} and N. Skill and Mary Maluccio",
year = "2010",
month = "11",
doi = "10.1111/j.1477-2574.2010.00207.x",
language = "English",
volume = "12",
pages = "625--636",
journal = "HPB",
issn = "1365-182X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma

AU - Wu, Jian Min

AU - Skill, N.

AU - Maluccio, Mary

PY - 2010/11

Y1 - 2010/11

N2 - Objectives: Lipids are linked to many pathological processes including hepatic steatosis and liver malignancy. This study aimed to explore lipid metabolism in hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). Methods: Serum lipids were measured in normal, HCV and HCV-HCC patients. Whole-genome microarray was performed to identify potential signature genes involved in lipid metabolism characterizing normal vs. HCV vs. HCV-HCC conditions. Results: Serum cholesterol was significantly reduced in HCV and HCV-HCC patients compared with normal controls, whereas there was no difference in glucose and triglycerides. Microarray analysis identified 224 probe sets with known functional roles in lipid metabolism (anova, 1.5-fold, P ≤ 0.001). Gene-mediated fatty acid (FA) de novo synthesis and uptake were upregulated in HCV and this upregulation was further enhanced in HCC. Genes involved in FA oxidation were downregulated in both the HCV and HCC groups. The abnormality of cholesterol metabolism in HCV was associated with downregulation of genes involved in cholesterol biosynthesis, absorption and transportation and bile acid synthesis; this abnormality was further intensified in HCC. Conclusions: Our data support the notion that HCV-related lipid metabolic abnormalities may contribute to hepatic steatosis and the development of cancer. Identification of these aberrations would stratify patients and improve treatment algorithms.

AB - Objectives: Lipids are linked to many pathological processes including hepatic steatosis and liver malignancy. This study aimed to explore lipid metabolism in hepatitis C virus (HCV) and HCV-related hepatocellular carcinoma (HCC). Methods: Serum lipids were measured in normal, HCV and HCV-HCC patients. Whole-genome microarray was performed to identify potential signature genes involved in lipid metabolism characterizing normal vs. HCV vs. HCV-HCC conditions. Results: Serum cholesterol was significantly reduced in HCV and HCV-HCC patients compared with normal controls, whereas there was no difference in glucose and triglycerides. Microarray analysis identified 224 probe sets with known functional roles in lipid metabolism (anova, 1.5-fold, P ≤ 0.001). Gene-mediated fatty acid (FA) de novo synthesis and uptake were upregulated in HCV and this upregulation was further enhanced in HCC. Genes involved in FA oxidation were downregulated in both the HCV and HCC groups. The abnormality of cholesterol metabolism in HCV was associated with downregulation of genes involved in cholesterol biosynthesis, absorption and transportation and bile acid synthesis; this abnormality was further intensified in HCC. Conclusions: Our data support the notion that HCV-related lipid metabolic abnormalities may contribute to hepatic steatosis and the development of cancer. Identification of these aberrations would stratify patients and improve treatment algorithms.

KW - Hepatic steatosis

KW - Hepatitis C virus (HCV)

KW - Hepatocellular carcinoma (HCC)

KW - Lipid metabolism

UR - http://www.scopus.com/inward/record.url?scp=78349277671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349277671&partnerID=8YFLogxK

U2 - 10.1111/j.1477-2574.2010.00207.x

DO - 10.1111/j.1477-2574.2010.00207.x

M3 - Article

VL - 12

SP - 625

EP - 636

JO - HPB

JF - HPB

SN - 1365-182X

IS - 9

ER -